Translate

Friday, December 6, 2019

thumbnail

KPTI Karyopharm Therapeutics Inc. gains 48% Dec 6, 2019

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.http://www.priceseries.com/trade/KPTI-Karyopharm-Therapeutics-Inc-stock-gains-48-percent-a-Trade-Record-by-priceSeries-2019102520191206.html
thumbnail

ICPT Intercept Pharmaceuticals, Inc. gains 36% Dec 6, 2019

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.http://www.priceseries.com/trade/ICPT-Intercept-Pharmaceuticals-Inc-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2019110620191206.html
thumbnail

FBIO Fortress Biotech, Inc. gains 38% Dec 6, 2019

Coronado Biosciences, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include Trichuris suis ova or...http://www.priceseries.com/trade/FBIO-Fortress-Biotech-Inc-stock-gains-38-percent-a-Trade-Record-by-priceSeries-2019110820191206.html
thumbnail

BCRX BioCryst Pharmaceuticals, Inc. gains 22% Dec 6, 2019

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.http://www.priceseries.com/trade/BCRX-BioCryst-Pharmaceuticals-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2019111920191206.html
thumbnail

AQXP Aquinox Pharmaceuticals, Inc. gains 16% Aug 9, 2019

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1 (SHIP1) enzyme, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder. The company was founded in 2003 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/AQXP-Aquinox-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019111820190809.html

Thursday, December 5, 2019

thumbnail

WVE WAVE Life Sciences Ltd. gains 40% Dec 5, 2019

thumbnail

REPH Recro Pharma, Inc. gains 57% Dec 5, 2019

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.http://www.priceseries.com/trade/REPH-Recro-Pharma-Inc-stock-gains-57-percent-a-Trade-Record-by-priceSeries-2019101520191205.html

TradeVisor Product Review

Review I II III IV

Blog Archive